Lunai Bioworks Pivots to AI Cancer Diagnostics After Key Acquisitions

TL;DR

**LNAI is a high-risk, pre-clinical biotech play betting big on AI cancer diagnostics and cell therapies; expect volatility and significant capital needs.**

AI Summary

Lunai Bioworks Inc. (LNAI) is a pre-clinical-stage biotechnology company that shifted its primary focus to AI-driven molecular diagnostics and oncology following the acquisition of GEDi Cube Intl on February 13, 2024, and BioSymetrics on April 8, 2025. The company reported an aggregate market value of voting and non-voting common equity held by non-affiliates of $111,903,627 as of December 31, 2024. Lunai Bioworks operates through three subsidiaries: Renovaro Biosciences, Renovaro Cube, and BioSymetrics. Renovaro Biosciences is developing allogeneic cell and gene therapies for solid tumors like pancreatic and triple-negative breast cancer (RENB-DC11 and RENB-DC20), currently in the pre-IND, IND-enabling phase. Renovaro Cube, acquired in February 2024, focuses on AI-driven early cancer detection, recurrence monitoring, treatment response prediction, and clinical trial support using a multi-omics approach. The company had 231,802,470 shares of common stock outstanding as of September 26, 2025, and continues to incur losses as it has no products with regulatory approval.

Why It Matters

Lunai Bioworks' strategic pivot to AI-driven cancer diagnostics and allogeneic cell therapies, following the acquisitions of GEDi Cube Intl and BioSymetrics, positions it in highly competitive and rapidly evolving sectors. For investors, this shift introduces both significant upside potential if its novel AI platform for early cancer detection proves effective, and substantial risk given its pre-clinical stage and continuous losses. Employees and customers could benefit from innovative diagnostic tools and therapies for deadly cancers, potentially transforming patient outcomes. The broader market will watch to see if Lunai's multi-omics, Explainable AI approach can disrupt established diagnostic methods and compete with larger biotech firms.

Risk Assessment

Risk Level: high — Lunai Bioworks is a pre-clinical-stage biotechnology company with no products that have achieved regulatory approval, indicating a high inherent risk. The filing explicitly states the company's 'continuous incurrence of losses' and 'dependence on substantial additional financing' to support research and development, highlighting significant financial instability. Furthermore, the company's reliance on 'third parties to research and develop product candidates' and the 'difficulty or impossibility of predicting future clinical trial results and regulatory outcomes' contribute to a high-risk profile.

Analyst Insight

Investors should approach LNAI with extreme caution, recognizing it as a highly speculative investment. Monitor progress on clinical trials for RENB-DC11 and RENB-DC20, and the commercialization efforts of Renovaro Cube's AI platform. Given the pre-clinical stage and reliance on future financing, consider a small, speculative position only if comfortable with potential total loss.

Financial Highlights

debt To Equity

N/A

revenue

$0

operating Margin

N/A

total Assets

$2,010,000

total Debt

$0

net Income

-$170,097,890

eps

N/A

gross Margin

N/A

cash Position

$1,425,000

revenue Growth

N/A

Key Numbers

• $111,903,627 — Aggregate market value of common equity held by non-affiliates (as of December 31, 2024)
• 231,802,470 — Shares of common stock outstanding (as of September 26, 2025)
• February 13, 2024 — Acquisition date of GEDi Cube Intl (marked the shift in primary company focus)
• April 8, 2025 — Acquisition date of BioSymetrics (expanded AI and data science capabilities)
• 2013 — Year Grace Systems B.V. (Renovaro Cube) was incorporated (initial development of data mining algorithms)
• 2018 — Year Grace Systems B.V. pivoted to healthcare (focused on applying algorithms to biological data for cancer)

Key Players & Entities

• Lunai Bioworks Inc. (company) — registrant
• GEDi Cube Intl Ltd (company) — acquired subsidiary, focus of new strategy
• BioSymetrics Inc. (company) — acquired subsidiary
• Renovaro Biosciences (company) — subsidiary developing cell and gene therapies
• Renovaro Cube (company) — subsidiary focused on AI-driven diagnostics
• The Nasdaq Stock Market LLC (regulator) — exchange where common stock is registered
• Private Securities Litigation Reform Act of 1995 (regulator) — governs forward-looking statements
• RENB-DC11 (product) — allogeneic dendritic cell therapeutic vaccine candidate
• RENB-DC20 (product) — allogeneic dendritic cell therapeutic vaccine candidate
• Grace Systems B.V. (company) — original incorporation of Renovaro Cube

FAQ

Risk Factors

• Significant Accumulated Deficit [high — financial]: As of December 31, 2024, the Company has an accumulated deficit of $170,097,890. This substantial deficit indicates that the Company has incurred more expenses than revenues since its inception, raising concerns about its long-term financial viability and ability to fund future operations without additional capital.
• Dependence on Key Personnel [medium — operational]: The success of Lunai Bioworks is heavily reliant on the continued service of its key management and scientific personnel, including Dr. S. Peter Lee, its Chief Executive Officer. The loss of any of these individuals could significantly disrupt the Company's research, development, and business strategies.
• Uncertainty of Product Approval [high — regulatory]: As a pre-clinical stage biotechnology company with no products currently approved by regulatory authorities, Lunai Bioworks faces significant uncertainty regarding the timeline and success of obtaining regulatory approval for its drug candidates. The development process is lengthy, expensive, and subject to stringent regulatory review.
• Intense Competition in Oncology and Diagnostics [high — market]: The fields of oncology and molecular diagnostics are highly competitive, with numerous established companies and emerging biotechs. Lunai Bioworks competes with entities that have greater financial resources, established market presence, and extensive experience in drug development and commercialization.
• Need for Future Financing [high — financial]: The Company anticipates that it will require substantial additional funding to finance its ongoing operations, research and development activities, and potential commercialization efforts. There is no assurance that such financing will be available on terms acceptable to the Company, or at all.
• Integration of Acquired Companies [medium — operational]: The Company has recently acquired GEDi Cube Intl and BioSymetrics, and its success depends on its ability to effectively integrate these businesses, technologies, and personnel. Failure to achieve successful integration could adversely affect its operations and strategic objectives.
• Intellectual Property Risks [medium — legal]: The Company's ability to protect its intellectual property is critical. There is a risk that its patents may not be sufficiently broad or that third parties may infringe upon its intellectual property rights, leading to costly legal disputes.

Industry Context

Lunai Bioworks operates in the highly competitive biotechnology sector, specifically focusing on AI-driven molecular diagnostics and oncology. The industry is characterized by rapid technological advancements, significant R&D investment, and a lengthy, complex regulatory approval process. Key trends include the increasing application of artificial intelligence and machine learning in drug discovery and diagnostics, and a growing demand for personalized medicine approaches.

Regulatory Implications

As a pre-clinical stage company with no approved products, Lunai Bioworks faces substantial regulatory hurdles. The development of its cell and gene therapies and AI diagnostic tools will require rigorous testing and adherence to strict FDA guidelines. Any delays or failures in the IND-enabling phase or subsequent clinical trials could significantly impact its timeline to market and financial resources.

What Investors Should Do

1. Monitor R&D progress and IND filings
2. Assess cash burn rate and future financing needs
3. Evaluate the integration and synergy of acquired entities
4. Analyze competitive landscape and differentiation

Key Dates

• 2024-02-13: Acquisition of GEDi Cube Intl — Marked a strategic shift towards AI-driven molecular diagnostics and oncology.
• 2025-04-08: Acquisition of BioSymetrics — Further expanded AI and data science capabilities, enhancing its multi-omics approach.
• 2024-12-31: Aggregate market value of common equity held by non-affiliates reported — Indicates the market's valuation of the company's equity at a specific point in time.
• 2025-09-26: Shares of common stock outstanding reported — Provides the total number of shares available, relevant for per-share calculations and market capitalization.

Glossary

Pre-clinical stage

Refers to the stage of drug development before human testing begins, involving laboratory and animal studies. (Indicates that Lunai Bioworks' lead drug candidates are still in the early stages of development and have not yet undergone human clinical trials.)

Allogeneic cell and gene therapies

Therapies that use cells or genetic material from a donor (allogeneic) rather than the patient's own (autologous) to treat diseases. (Describes the type of therapies being developed by Renovaro Biosciences for solid tumors.)

IND-enabling phase

The stage of research and development that generates the data required to submit an Investigational New Drug (IND) application to regulatory authorities like the FDA. (Shows that Renovaro Biosciences' therapies are progressing towards potential human testing.)

Multi-omics approach

An integrated analysis of different types of biological data, such as genomics, transcriptomics, proteomics, and metabolomics, to gain a comprehensive understanding of biological systems. (Highlights the sophisticated data analysis methodology used by Renovaro Cube for cancer detection and prediction.)

Accumulated deficit

The total cumulative net losses of a company since its inception, minus any cumulative net income. (A significant accumulated deficit, such as Lunai Bioworks' $170,097,890 as of December 31, 2024, indicates a history of unprofitability.)

Year-Over-Year Comparison

Information comparing key metrics to the previous year is not available in the provided text. However, the company has undergone significant strategic shifts with the acquisitions of GEDi Cube Intl in February 2024 and BioSymetrics in April 2025, indicating a pivot towards AI-driven diagnostics and oncology. This suggests a potential change in operational focus and investment priorities compared to prior periods.

Key Financial Figures

• $0.0001 — ch Registered Common Stock, par value $0.0001 per share RENB The Nasdaq Stock Mar

Filing Documents

• e6882_10-k.htm (10-K) — 1847KB
• e6882_ex21-1.htm (EX-21.1) — 4KB
• e6882_ex23-1.htm (EX-23.1) — 3KB
• e6882_ex31-1.htm (EX-31.1) — 9KB
• e6882_ex31-2.htm (EX-31.2) — 9KB
• e6882_ex32-1.htm (EX-32.1) — 4KB
• e6882_ex32-2.htm (EX-32.2) — 4KB
• image_001.jpg (GRAPHIC) — 41KB
• image_002.jpg (GRAPHIC) — 41KB
• image_003.jpg (GRAPHIC) — 114KB
• image_004.jpg (GRAPHIC) — 18KB
• image_006.jpg (GRAPHIC) — 53KB
• 0001731122-25-001316.txt ( ) — 9429KB
• renb-20250630.xsd (EX-101.SCH) — 73KB
• renb-20250630_cal.xml (EX-101.CAL) — 60KB
• renb-20250630_def.xml (EX-101.DEF) — 305KB
• renb-20250630_lab.xml (EX-101.LAB) — 534KB
• renb-20250630_pre.xml (EX-101.PRE) — 477KB
• e6882_10-k_htm.xml (XML) — 1280KB

Business

Business 1 Item 1A Risk Factors 18 Item 1B Unresolved Staff Comments 50 Item 1C Cybersecurity Risk Management and Strategy 50 Item 2

Properties

Properties 51 Item 3 Legal Proceedings 52 Item 4 Mine Safety Disclosures 54 Part II 55 Item 5 Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 55 Item 6 Selected Financial Data 55 Item 7 Management's Discussion and Analysis of Financial Condition and Results Of Operations 55 Item 7A Quantitative and Qualitative Disclosures About Market Risk 63 Item 8 Financial 63 Item 9 Changes In and Disagreements with Accountants on Accounting and Financial Disclosure 64 Item 9A Controls and Procedures 64 Item 9B Other Information 64 Part III 65 Item 10 Directors, Executive Officers and Corporate Governance 65 Item 11 Executive Compensation 65 Item 12 Security 65 Item 13 Certain Relationships and Related Transactions and Director Independence 65 Item 14 Principal Accountant Fees and Services 65 Part IV 66 Item 15 Exhibits, Financial Statement Schedules 66

Signatures

Signatures and Certifications 69 i Cautionary Language Regarding Forward-Looking Statements and Industry Data This Annual Report on Form 10-K contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 regarding the plans and objectives of management for future operations and market trends and expectations. Forward-looking statements can be identified by the fact that they do not relate strictly to historical or current facts. Forward-looking statements are based upon our current assumptions, expectations and beliefs concerning future developments and their potential effect on our business. In some cases, you can identify forward-looking "intend," "plan," "anticipate," "believe," "approximately," "estimate," "predict," "project," "potential" or the negative of these terms or other comparable terminology, although the absence of these words does not necessarily mean that a statement is not forward-looking.

Forward-looking statements include,

Forward-looking statements include, but are not limited to, statements concerning: Our ability to continue as a going concern and ability to raise additional capital; Our continuous incurrence of losses as a pre-clinical-stage biotechnology company with no products that have achieved regulatory approval; Our ability to generate revenue if we fail to develop marketable product; Our dependence on substantial additional financing to support the research, development, licensing, manufacture, and marketing of product candidates and products, and the possibility that unforeseen operational costs will arise; The dilutive effect on stockholders' ownership interests of the Company raising capital through an equity issuance in connection with future equity financing or equity debt agreements; Our dependence on the services of experts, including third parties to research and develop product candidates in cooperation with our employees and officers; The difficulty or impossibility of predicting future clinical trial results and regulatory outcomes of our products based upon our pre-clinical or earlier clinical trial performance; The application of heightened regulatory and commercial scrutiny to our AI-based technology, gene, cell, and immunotherapy products given their novel nature and concomitant potential for actual or perceived safety issues; Our ability to compete in rapidly developing fields, and the potential impact to our financial condition, product marketability, and operational capacities of a competitor receiving regulatory approval before us, or a competitor developing more advanced or efficacious products; Potential delays or total failures of third parties, such as universities, non-profits, and clinical research centers, to perform obligations on which our product research and development rely; The impact on our competitive position, business operations, and financial condition of implementation of amended healthcare laws and regulations;

View Full Filing

View this 10-K filing on SEC EDGAR